Research summary ·
Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review looked at heart-related immune side effects of immune checkpoint inhibitors. These are called cardiovascular irAEs. The team searched PubMed and Embase up to April 1, 2024. They studied 116 case reports from 115 studies. They noted the most common side effects, the treatments used and the outcomes.
What they found
Myocarditis was the most common problem. It often came with pericarditis and heart failure. Treatment usually included corticosteroids and stopping the ICI drug. Higher steroid doses seemed to give better results. Hard cases improved with plasmapheresis, immunoglobulin, mycophenolate, tacrolimus or infliximab. Restarting ICI therapy gave mixed outcomes.
What it means for patients
The authors say data on these side effects vary a lot. They say pooled data from central registries would be very useful. One example is the Side Effect Registry Immuno-Oncology, called SERIO.
Why it is not certain yet
The studies were case reports and series. The abstract says data from trials and real-world studies vary widely. The abstract gives no rates of events. Outcomes of restarting therapy were mixed.
Source
Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports.
PubMed · PMID 42754915We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Myocarditis publications